BETA: Please send your feedback!

Vanda Pharmaceuticals

NAS:VNDA

Biotechnology

$1.09bn
SMALL cap
$20.80 (3.84%)
-23.02%
since start of 2019
43.33
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 1
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5

About

Vanda Pharmaceuticals, Inc. is a global biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve the lives of patients. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
website

Headquarters

2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037

Executives

Name Title Gender
H. Thomas Watkins, MBA Chairman Male
Chip Clark, MBA Founder Male
Argeris N. Karabelas, PhD Founder Male
Mihael Hristos Polymeropoulos, MD President, Chief Executive Officer & Director Male
James Patrick Kelly, CFA, MBA Chief Financial Officer, Treasurer & Senior VP Male
Richard L. Gulino Secretary, Senior VP & General Counsel Male

Mindful Investing Summary

  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint N/A
  • Pollution Prevention N/A
  • Water Conservation N/A
  • Data & Privacy Protection N/A
  • Consumer Health, Wellness & Safety N/A
  • Employee Ownership, Satisfaction, Benefits & Pay N/A
  • Workplace Health and Safety N/A
  • Integrity of Corporate Governance N/A
  • Ethical Practices N/A
  • Usage of Conflict Materials N/A
  • Forced Labor N/A
  • Diversity of Corporate Leadership 1

Vanda Pharmaceuticals - Competitors and Related Companies

How Vanda Pharmaceuticals stacks up to its peers in the Biotechnology industry or with competing business segments.

Vanda Pharmaceuticals

NAS:VNDA

Biotechnology

$1.09bn
SMALL cap
$20.80 (3.84%)
-23.02%
since start of 2019
43.33
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 1
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5
Loading…